WDI: Uncertain Outlook Reduces Appeal (Rating Downgrade)
WDI's rating is downgraded amid prolonged high-interest rates. Learn about potential risks, NAV discount changes & dividend ...
Exelixis: Cabozantinib Continues To Grow, Zanzalintinib Could Soon Follow
Exelixis reported $515.2M in net product revenues in Q4'24, a 20% increase over net product revenues for Q4'23. See why I ...